Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo

Drug Delivery

Volumn 20, Issue 2, 2013, Pages 78-85

  Riehle, Robert D ^a   Cornea, Sinziana ^b   Degterev, Alexei ^b   Torchilin, Vladimir ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Multifunctional drug delivery; PEG PE micelles; PIP3 antagonists; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; DM PIT 1; MACROGOL; MACROGOL 2000; N [(2 HYDROXY 5 NITROPHENYL)AMINO]CARBONOTHIOYL 3,5 DIMETHYLBENZAMIDE DERIVATIVE; NCL 176; NCL 179; NCL 198; NCL 240; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICELLE; MOUSE; NONHUMAN; OVARY CARCINOMA; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MICELLES; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLINOSITOL 3-KINASE; SOLUBILITY; SURFACE PROPERTIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875754440     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.766780     Document Type: Article

References (26)

1. Bagci-Onder T, Wakimoto H, Anderegg M, et al. (2011). A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 71:154-63.
2. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296:1655-7.
3. Cornea S, Ramana CV, Degterev A. (in preparation). Optimization of heterocyclic derivatives of PITENIN-1.
4. Dalmoro A, Barba AA, Lamberti G, et al. (2012). Pharmaceutical applications of biocompatible polymer blends containing sodium alginate. Adv Polym Technol 31:219-30.
5. Ding W, Cai T, Zhu H, et al. (2010). Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett 293:158-66.
6. Fang J, Nakamura H, Maeda H. (2011). The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136-51.
7. Ganapathy S, Chen Q, Singh KP, et al. (2010). Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 5:e15627.
8. Hellwig CT, Rehm M. (2012). TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Therap 11:3-13.
9. Johnstone RW, Frew AJ, Smyth MJ. (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782-98.
10. McNamara CR, Degterev A. (2011). Small-molecule inhibitors of the PI3K signaling network. Future Med Chem 3:549-65.
11. Miao B, Skidan I, Yang J, et al. (2010). Small molecule inhibition of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci USA 107:20126-31.
12. Pan G, Ni J, Wei YF, et al. (1997a). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-18.
13. Pan G, O'rourke K, Chinnaiyan AM, et al. (1997b). The receptor for the cytotoxic ligand TRAIL. Science 276:111-13.
14. Reulen SWA, Merkx M. (2010). Exchange kinetics of protein-functionalized micelles and liposomes studied by forster resonance energy transfer. Bioconj Chem 21:860-6.
15. Sawant RR, Torchilin VP. (2010a). Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol 27:232-46.
16. Sawant RR, Torchilin VP. (2010b). Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol 624:131-49.
17. Sawant RR, Torchilin VP. (2011). Design and synthesis of novel functional lipid-based bioconjugates for drug delivery and other applications. Methods Mol Biol 751:357-78.
18. Skidan I, Grunwald J, Thekkedath R, et al. (2011). A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3, 5-dimethylbenzamide in biological samples. J Chromatogr B: Analyt Technol Biomed Life Sci 879:1610-16.
19. Skidan I, Miao B, Thekkedath RV, et al. (2009). In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 16:45-51.
20. Song MS, Salmena L, Pandolfi PP. (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13:283-96.
21. Torchilin VP. (2005). Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2:319-27.
22. Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131-5.
23. Torchilin VP, Levchenko TS, Lukyanov AN, et al. (2001). p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim et Biophys Acta (BBA)-Biomem 1511:397-411.
24. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
25. Wymann MP, Marone R. (2005). Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17:141-9.
26. Zhang L, Fang B. (2004). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12:228-37.